RecruitingPhase 4NCT06128915
The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
Sponsor
State University of New York at Buffalo
Enrollment
60 participants
Start Date
Jan 8, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
Eligibility
Min Age: 21 Years
Inclusion Criteria7
- Both sexes
- Have not been vaccinated with any licensed or experimental pneumococcal vaccine
- Ages 21-40; and ≥65. Individuals >60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
- Free of acute infections within the last 2 weeks
- Did not take any anti-inflammatory medicine in the last week
- Did not ingest alcohol in the last 24 hours
- Ability and willingness to provide consent
Exclusion Criteria10
- Previous vaccination with any licensed or experimental pneumococcal vaccine
- Known hypersensitivity to vaccination and vaccine components
- Immune deficiency
- Use of immune-modulating or suppressive drugs
- Malignancies within the last 2 years
- Known hematological, rheumatic and inflammatory diseases
- Known chronic infections
- Poorly controlled chronic cardiovascular and metabolic conditions
- Pregnancy
- Dementia
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERvaccine
Vaccination against 20 serotypes of S. pneumoniae
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06128915
Related Trials
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
NCT070990531 location
Ketone Ester And Salt (KEAS) in Older Adults
NCT068687191 location
Older Age and Generalization
NCT074400171 location
Baltimore Longitudinal Study of Aging
NCT002332721 location
100-Year Human Aging Study
NCT075637771 location